This one is different. ROSG is the marketing partner, using their connections with providers to sell gene based tests. Don't know about you, but I'm thoroughly confused. In past PRs they announce partnerships to sell the ROSG tests. Now they are going to be selling another company's tests.
As usual however, no specific financials are provided. No surprise, the market is sleeping through this PR again.7K traded, or about $20,000 worth. Of course that might equal total sales generated by this "deal."
The Fed looks a bit more hawkish, but read between the lines: the economy is getting better. There will be some inflation and that means commodity prices will go up. If everyone thinks that CLF price is ore price dependent, isn't this the signal that prices are going up and accordingly CLF margins should improve as well.
And now stuck at 29 with very few options open this week. Yup, I think there are better places to put your money.: coal, for example.
There isn't enough value left in this company to sue it. Once again, the market is racing higher and no one has any faith in ROSG to buy at the ask.
A few weeks ago an analyst put a $5 price target on CLF. I wonder, was that an attempt to drive down the price so that the analyst's clients could get in cheap? It is a good strategy and whenever we see a target that is significantly higher or lower than the current price, I have to assume there is a hidden, contrary agenda.
Incorrect proxies? You have to wonder what a CEO and BOD are doing that they don't have time to check this simple, yet important administrative function.
Even the coal stocks like WLT, BTU and ACI are doing better than CLF today. And we thought that CLF numbers were pretty good, given estimates? There are just some companies that some folks love to hate.
Lost that a long time ago; it is just that they reported it recently. The problem? You conveniently fail to read the company's PRs. Strong Ignore.
Delayed or did the bar for approval just get moved up? I don't understand exactly what additional data the FDA is requiring, but doesn't it seem that they aren't inclined to bless new science?
Don't believe it. N management believes that every other company is using last generation technology and won't catch up. They are managing in the AMZN mode: i.e. continuing to focus on growth. As long as Wall Street rewards growth, they'll do just fine. Profits are only important if your growth slows.
Sales are up and GAAP losses are up too. Nevertheless:
"The shift from antiquated software such as SAP and Microsoft to NetSuite's modern cloud-native solution is transforming the capabilities of small, medium and large organizations around the globe."
Whether you're looking at GAAP or non-GAAP earnings, I'm not sure of why folks are buying in AH.
Yet another partnership and I didn't have to read the PR to know that, once again, it would not include any financial data. In the past, such announcements would get some buying interest. I don't think we'll see any increase in volume today. 50K shares max and even with a good market today, maybe it'll close a penny or two above 3. I think they should change the trading symbol from ROSG to JOKE.
GS initiated coverage with a neutral rating and target of 6. I don't know what that means. Does it mean the current value is 6? If it is neither a buy or sell, does it mean ignore?
Will this be the big surprise announcement? I'm tempted to add some more, even though I have been burned on bumps more times than I can count.